TheEdgeResearch
Home / Stocks / SNN

Smith & Nephew plc (SNN)

NYSE Healthcare Medical - Devices
$29.83 ▲ +0.00%
Market Cap
$12.48B
Sector
Healthcare
Industry
Medical - Devices
Beta
0.69
52-Wk Range
26.12-37.09
CEO
Deepak S. Nath
Country
GB
Currency
USD

Smith & Nephew plc operates in the Medical - Devices industry of the Healthcare sector, headquartered in Watford, HRT, GB. The stock last traded at $29.83, up 0.00% on the session, giving a market capitalisation of $12.48B. On trailing twelve-month figures it carries a trailing P/E of 19.72, a net margin of 10.1%. Its beta of 0.69 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
19.72
Price / Sales
1.96
Price / Book
2.44
EV / EBITDA
9.39
Gross margin
68.2%
Operating margin
16.7%
Net margin
10.1%
Return on equity
—
Debt / equity
0.73
Current ratio
2.14
Dividend yield
2.6%
Payout ratio
52.3%
Company profile
Exchange
New York Stock Exchange
Employees
18,362
IPO date
1999-11-16
Headquarters
Watford, HRT, GB
About Smith & Nephew plc

Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.

Comparable companies

Smith & Nephew plc is most often compared with the following Healthcare names:

ATECCNMDENOVGMEDIARTKIDSOFIXSYKXTNTZBH
More research on SNN
SNN technical analysis SNN TheEdge Score Compare against peers
Open full interactive analysis & DCF →